Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and eval ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...

Endpoint Detection and Response (EDR) firm Cybereason and managed security services provider (MSSP) Trustwave announced plans to merge.

N4 Architecture talks about the design of its Birch Pavilion, which provides a space for work, relaxation and listening to ...

"We offer MSPs a layer of value with secure, modern endpoint management, powered by both Microsoft Intune and Devicie and we ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

Kaseya VSA offers several monitoring and patch management functions, making it a complete RMM platform. You get the benefits ...

Ivanti is patching numerous security vulnerabilities in various products, some of which are critical. IT managers should take ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

The Data Monitoring Committee (DMC) of the BHF-PROTECT-TAVI trial determined “there is little prospect of demonstrating a benefit in the primary endpoint.” Moreover, given the confidence intervals, ...